Please use this identifier to cite or link to this item:http://hdl.handle.net/20.500.12105/15766
Title
Reply: Biological Plausibility Behind the Benefits of Intravenous Metoprolol in Severe COVID-19.
Author(s)
Date issued
2022-01-04
Citation
J Am Coll Cardiol. 2022 Jan 4;79(1):e13-e14
Language
Inglés
Document type
journal article
MESH
COVID-19 | Metoprolol | Administration, Intravenous | Adrenergic beta-1 Receptor Antagonists | Humans | SARS-CoV-2
Online version
DOI
Collections